Cannabis After Schedule III: What PM&R Physicians Need to Know Now

Friday, November 13, 2026

1:30 PM - 2:45 PM ET

Session Director(s)

Stuart J. Glassman, MBA, MD (he/him/his)

President/Owner
Granite Physiatry, PLLC
Bedford, New Hampshire

Disclosure(s): No financial relationships to disclose

Faculty(s)

Michael Saulino, MD, PhD

Professor and Chair
Cooper University Hospital
Havertown, Pennsylvania

Disclosure information not submitted.
Gregory T. Carter, MD, MS (he/him/his)

Chief Medical Officer and Residency Associate Director
Providence St. Luke's Medical Center PM&R Program
Spokane, Washington

Disclosure(s): No financial relationships to disclose

Disclosure(s):

Stuart J. Glassman, MBA, MD: No financial relationships to disclose

Gregory T. Carter, MD, MS: No financial relationships to disclose

Session Description: This session is designed to help physiatrists accurately interpret federal cannabis reclassification, recognize the growing relevance of Medical Cannabis to everyday PM&R practice, and understand why foundational literacy in Cannabinoid Medicine is now necessary. This course establishes a common clinical framework for assessing potential benefits, limitations, and functional risks within rehabilitation populations. It also highlights emerging opportunities for PM&R leadership in education and research as regulatory barriers diminish and scientific inquiry expands.

Learning Objectives:

Describe the historical evolution of cannabis as a medicinal agent, from ancient therapeutic use through federal prohibition under the Controlled Substances Act of 1970 and subsequent state-level medical adoption.
Improve awareness of the most recent legislative issues relative to the Federal rescheduling of cannabis.
Review Federal workplace drug testing regulations in relation to the rescheduling of cannabis.
Enhance understanding of the impact of cannabis rescheduling on Veterans health care and PM&R practice.
Identify how Schedule III reclassification reduces regulatory barriers to clinical research and expands opportunities for physiatrists for evidence-based investigation of cannabinoid therapies.